NCT06652139View on ClinicalTrials.gov

Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2028

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

selinexor combined with BEAM regimen

Selinexor: 60mg po D-10, D-7 and D-4 Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2

DRUG

BEAM regimen

Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT06652139 - Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive | Biotech Hunter | Biotech Hunter